| Organism | Drug Class | Sponsor and/or Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Epstein-Barr virus | Combination | | Phenylbutyrate and Valganciclovir | | Phase 2 | Unknown | |
| Epstein-Barr virus | Combination | HemaQuest Pharmaceuticals Inc. | Ganciclovir and Arginine Butyrate | | Phase 2 | Terminated | |
| Epstein-Barr virus | Virus Replication Inhibitor | GSK | Valtrex™ | Valacyclovir | Phase 3 | Completed |
070982
|
| Herpes simplex virus | Blocks Virus morphogenesis | DeNova Research | Botox™ | Botulinum Toxin A; Onabotulinumtoxin A | Phase 2 | Completed | |
| Herpes simplex virus | DNA Helicase Inhibitor | AiCuris | Pritelivir | AIC-316 | Phase 2 | Terminated | |
| Herpes simplex virus | Entry Inhibitor | Shaman Pharmaceuticals | Virend™ | Crofelemer; SP-303T | Phase 2 | Completed |
071298
|
| Herpes simplex virus | Helicase-primase Inhibitor | Astellas Pharma Inc | ASP2151 | | Phase 3 | Recruiting |
501812
|
| Herpes simplex virus | Unknown | Zicam | Zicam™ | Ionic Zinc | Phase 3 | Completed | |
| Herpes simplex virus | Virucidal | NanoBio Corporation; GlaxoSmithKline | NB-001 | | Phase 3 | Completed | |
| Herpes simplex virus | Virus Replication Inhibitor | Oclassen Pharmaceuticals | Fialuridine | FIAU | Phase 2 | Completed |
070971
|
| Herpes simplex virus | Virus Replication Inhibitor | Beech Tree Labs, Inc. | BTL-TML-HSV | | Phase 2 | Completed | |
| Herpes simplex virus | Virus Replication Inhibitor | Gilead Sciences | Forvade™ | Cidofovir gel | Phase 2 | Completed |
001049
|
| Herpes simplex virus | Virus Replication Inhibitor | Parkedale Pharmaceuticals | Vira-A™ | Vidarabine | Phase 3 | Completed |
007328
|
| Human cytomegalovirus | HCMV Maturation Inhibitor | Bayer | BAY 38-4766 | | Preclinical | |
085779
|
| Human cytomegalovirus | HCMV Replication Inhibitor | Trifecta Pharmaceuticals | Artesunate | | Phase 3 | Completed |
112081
|
| Human cytomegalovirus | HCMV Terminase-Complex Inhibitor | AiCuris | Letermovir | AIC246 | Phase 3 | Recruiting |
499605
|
| Human cytomegalovirus | UL97 Kinase Inhibitor | GlaxoSmithKline, ViroPharma | Maribavir | Benzimidavir; 1263W94; G1263 | Phase 3 | Completed |
070966
|
| Human cytomegalovirus | Virus Replication Inhibitor | Chimerix | Brincidofovir | CMX001; Cidofovir prodrug | Phase 3 | Recruiting |
104906
|
| Human cytomegalovirus | Virus Replication Inhibitor | Microbiotix, Inc.; Karmanos Cancer Institute | Cyclopropavir | CPV;ZSM-I-62 MBX400 | Phase 1 | Completed |
165691
|
| Human cytomegalovirus | Virus Replication Inhibitor | Gilead Sciences | Preveon™; Hepsera™ | Adefovir Dipivoxil; bis-POM PMEA | Phase 3 | Completed |
028595
|
| Kaposi sarcoma virus | Matrix Metalloproteinase Inhibitor | Bristol-Myers Squibb | Rebimastat | BMS-275291 | Phase 2/3 | Completed | |
| Kaposi sarcoma virus | Protease Inhibitor | Merck | Crixivan™ | Indinavir | Phase 2 | Active, Not Recruiting |
005824
|
| Kaposi sarcoma virus | Tyrosine Kinase Inhibitor | Novartis | Gleevec™ | Imatinib Mesylate | Phase 2 | Completed |
553065
|
| Kaposi sarcoma virus | VEGF Modulator | PTC Therapeutics | PTC299 | | Phase 1/2 | Terminated | |